Maegim한국어

유한양행

000100KOSPISector: Pharma & Biotech
₩69,600▲ 0.58%Market cap ₩5.54TAs of Jul 21, 2026 close · updated once daily
B
Grade B63.3 ptsTop 26% of 2,523 stocks
Financial strength
68.0
Growth momentum
70.2
Price attractiveness
52.9

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

68.0
How much debt does it carry relative to equity?
Debt-to-equity ratio
36.3%
✓ Above median · Top 32.3% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
206.1%
✓ Above median · Top 46.1% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
4.8%
✓ Above median · Top 30.2% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
7.8%
✓ Above median · Top 19.3% in sector
Sector median -4.5%

Source filing: annual report (consolidated) — view original ↗

2

Growth momentum

70.2
How much did revenue grow in a year?
Revenue growth (YoY)
5.7%
✗ Below median · Top 54.1% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
7.2%
✓ Above median · Top 42.6% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
90.2%
✓ Above median · Top 14.1% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
189.7%
✓ Above median · Top 8.3% in sector
Sector median 3.5%

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

52.9
Is the price expensive relative to earnings?
P/E (price-to-earnings)
29.9x
✓ Above median · Top 31.5% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
2.35x
✗ Below median · Top 62.8% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15